Ofatumumab

Drug Overview

Ofatumumab (brand names Arzerra and Kesimpta) is a fully humanized type I anti-CD20 monoclonal antibody. It is designed to target the CD20 antigen, a protein highly expressed on the surface of both healthy and malignant B-lymphocytes. By binding to a unique “small-loop” epitope on the CD20 molecule, ofatumumab triggers a potent immune response that leads to the rapid depletion of B-cells.

In the clinical landscape of March 2026, ofatumumab occupies a unique dual role in medicine. Originally developed and approved for the treatment of Chronic Lymphocytic Leukemia (CLL), it has more recently been revolutionized as a high-efficacy, self-administered treatment for Multiple Sclerosis (MS). Its fully humanized structure—meaning it contains no mouse proteins—significantly reduces the risk of patients developing “anti-drug antibodies,” allowing it to remain effective over many years of chronic treatment.

• Generic Name: Ofatumumab.
• Brand Names: Arzerra (Oncology); Kesimpta (Neurology).
• Drug Class: CD20-directed Cytolytic Monoclonal Antibody; B-cell Depleting Therapy.
• Mechanism: Binding to a unique CD20 epitope to induce Complement-Dependent Cytotoxicity (CDC) and Antibody-Dependent Cellular Cytotoxicity (ADCC).
• Route of Administration: Intravenous (IV) infusion (Arzerra); Subcutaneous (SC) injection (Kesimpta).
• FDA Approval Status: FDA-approved (Initial oncology approval: 2009; MS approval: 2020).

What Is It and How Does It Work? (Mechanism of Action)

Ofatumumab works by “tagging” B-cells for destruction by the body’s own immune system.

1. The “Small-Loop” Binding

Unlike first-generation antibodies like rituximab, ofatumumab binds to a very specific part of the CD20 protein called the “small loop.” * Tighter Binding: Because it sits closer to the cell membrane, ofatumumab binds more tightly and is less likely to “fall off” the B-cell.

• Enhanced Potency: This proximity makes it exceptionally good at activating the “complement system,” a part of the immune system that can punch holes directly into the cancer cell’s membrane.

2. Complement-Dependent Cytotoxicity (CDC)

Ofatumumab is arguably the most potent “CDC-inducer” in its class.

• The “Hole-Punch” Effect: Once bound, it recruits proteins from the blood (complement) that assemble into a “membrane attack complex,” which kills the B-cell almost instantly.

3. Antibody-Dependent Cellular Cytotoxicity (ADCC)

Like other monoclonal antibodies, it also acts as a “flag” for Natural Killer (NK) cells and macrophages, which swallow and destroy the targeted B-cells.

FDA Approved Clinical Indications (2026)

As of March 2026, ofatumumab is utilized in two very different clinical areas:

1. Oncology (Arzerra)

• Chronic Lymphocytic Leukemia (CLL): Approved for patients whose disease has returned after prior treatment, or in combination with chlorambucil for previously untreated patients who cannot receive intensive chemotherapy.
• Extended Treatment (Maintenance): Approved for patients who are in complete or partial response after at least two lines of therapy to delay the return of the leukemia.

2. Neurology (Kesimpta)

• Relapsing Forms of Multiple Sclerosis (RMS): Approved for adults with relapsing-remitting disease and active secondary progressive disease. Its self-administered subcutaneous form has become a standard of care for its convenience and high efficacy in preventing MS relapses.

Dosage and Administration Protocols

The dosing of ofatumumab varies significantly depending on whether it is being used for leukemia or multiple sclerosis.

Clinical Efficacy and Research Results (2024–2026)

Recent data has emphasized ofatumumab’s long-term safety and neurological “NEDA” (No Evidence of Disease Activity) status:

• ASCLEPIOS Long-term Data (2025): Five-year follow-up data has shown that patients on ofatumumab for MS have a 30-40% lower risk of disability progression compared to those on older oral therapies.
• CLL Combinations: Recent trials in 2024–2025 have explored combining low-dose ofatumumab with BTK inhibitors (like ibrutinib) in elderly patients, showing excellent tolerability and deep molecular remissions.
• Pediatric Research: Ongoing 2026 studies are evaluating the safety of subcutaneous ofatumumab in pediatric-onset Multiple Sclerosis.

Safety Profile and Side Effects

The primary risk of ofatumumab, like all B-cell depleters, is an increased vulnerability to certain infections.

Common Side Effects (>20%):

• Infusion/Injection Reactions: Fever, chills, and rash (mostly during the first dose).
• Respiratory Infections: Common cold, sinus infections, and bronchitis.
• General: Headache, fatigue, and muscle pain.

Serious Risks and Boxed Warnings:

• Hepatitis B Reactivation: All patients must be screened for HBV. The drug can cause a dormant virus to “wake up,” which can be fatal.
• Progressive Multifocal Leukoencephalopathy (PML): A rare, often fatal brain infection caused by the JC virus. While extremely rare with ofatumumab, it is a known risk for all CD20-targeted drugs.
• Hypogammaglobulinemia: Long-term use can lower the level of protective antibodies (IgG) in the blood, potentially requiring IV immunoglobulin (IVIG) therapy.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, ofatumumab is used to study “B-cell Reconstitution.” Researchers are investigating how the bone marrow “re-grows” a healthy B-cell population after the drug is stopped. In 2026, there is also intense focus on “Personalized Dosing.” Scientists are using B-cell monitoring (measuring CD19 levels) to see if some MS patients can go 6 or 8 weeks between doses instead of 4, reducing the overall immune suppression. Furthermore, studies are exploring the use of ofatumumab in Kidney Transplant patients to prevent “antibody-mediated rejection.”

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• HBV Screening: HBsAg and anti-HBc testing is mandatory.
• Baseline Labs: Quantitative immunoglobulin levels (IgG/IgM).

“Do’s and Don’ts” List:

• DO keep your Kesimpta pens in the refrigerator (2°C to 8°C); they can be left out for up to 7 days before use, but should not be put back in the fridge once they reach room temperature.
• DO report any new “weakness on one side” or “clumsiness” immediately, as these can be signs of the rare PML brain infection.
• DON’T receive any live vaccines (like certain flu mists or the yellow fever vaccine) while on this drug.
• DON’T ignore a fever; even a “mild” cold can become more serious when your B-cells are depleted.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Ofatumumab (Arzerra/Kesimpta) is a potent immune-modifying medication that requires close monitoring by an oncologist or neurologist. Always consult with your healthcare provider regarding your specific diagnosis, treatment plan, and infection-prevention strategies.